Introduction: Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive memory loss and mental deterioration. AD is the most common form of presenile dementia and is estimated to affect more than 4.7 million Americans. Due to the increasing cost of health care and the age of onset of those affected, Alzheimer's disease has become a serious problem nationwide. In 2013, the Center for Disease Control (CDC) estimated that approximately $203 billion was spent on AD-related health care. The CDC also estimates that by 2050 the number of affected people nationwide will quadruple, and further estimates a national expenditure of US$1.1 trillion (PMID 23507120). The cause of AD remains unidentified despite the best efforts of doctors and researchers to identify it. its cause or a method of treatment. The CDC has identified AD as the sixth leading cause of death in the United States, after cancer, heart disease, lung disease, and accidents (PMID 23507120). However, unlike Alzheimer's disease, science has made incremental advances in the care and treatment of people suffering from the other five major causes. Soon, the country is expected to see AD move up the ranks of the country's leading causes of death. Currently, there is no known cure for AD or any way to slow its progression. An affected person lives on average 8 years from the appearance of the first symptoms (PMID: 19836639). The mechanisms involved in AD pathology are still largely unknown. However, science knows that the beta-amyloid (Aβ) peptide is involved in at least some of the pathologies observed in the course of the disease. Evidence for the involvement of Aβ in AD is expressed through the widespread accumulation of the Aβ peptide throughout........a cause that leads to AD is imminent. When analyzing all the different pathologies caused by the Aβ peptide in unison, suggests that it may be incorrect to view AD as an individual disease, but as a spectrum disorder, which causes the overall deficits so often observed in AD victims. Additionally, the development of CAA occurs in 90% of AD patients (PMID: 3551211). This comorbidity of AD and CAA or any other amyloid-related pathology suggests that the interaction between developing diseases plays an important role in the prognosis of AD. The importance of identifying dysfunctions associated with APP gene mutations is crucial for understanding AD. In doing so, it gives scientists the ability to discern whether a dysfunction found in AD pathology is a result caused by the disease itself or whether it may be a potential cause of AD...